Notably, research has demonstrated that the modulation of microRNA‐146a (miR‐146a) expression impacts innate inflammation, effectively halts atherosclerosis progression, and enhances plaque stability by targeting interleukin‐1 receptor‐associated kinase (IRAK) and activating TNF receptor‐associated factor 6 (TRAF6), a signalling pathway involving toll‐like receptors (TLRs). This evidence concerns the gene IRAK1 and atherosclerosis.